| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2077961 | Cell Stem Cell | 2011 | 4 Pages |
Abstract
The Food and Drug Administration (FDA) has sought an injunction to prevent a US-based company from offering an autologous adult stem cell treatment for musculoskeletal and spinal injuries. Given the alarming number of clinics promoting stem-cell-based interventions, the outcome of this case could have wide-ranging implications.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Tamra Lysaght, Alastair V. Campbell,